MedTrace Logo

A Clinical Study Evaluating the Safety and Efficacy of GT801 Injection in Adult Patients With Relapsed/Refractory CD19-positive B-cell Hematologic Malignancies and Autoimmune Hemolytic Anemia

NCT07205315 · Status: RECRUITING · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 28

Last updated 2026-04-23

No results posted yet for this study

Summary

The goal of this clinical study is to evaluate the safety and efficacy of GT801 injection in adult patients with relapsed/refractory CD19-positive B-cell hematologic malignancies and autoimmune hemolytic anemia.

Conditions

  • B-cell Acute Lymphoblastic Leukemia (B-ALL)
  • Chronic Lymphocytic Leukemia (CLL)
  • B-cell Non-Hodgkin's Lymphoma (B-NHL)
  • Autoimmune Hemolytic Anemia (AIHA)

Interventions

BIOLOGICAL

GT801 Injection

GT801 Injection

Sponsors & Collaborators

  • Zhengzhou Yihe Hospital

    collaborator UNKNOWN

  • Institute of Hematology & Blood Diseases Hospital, China

    collaborator OTHER

  • Vivacta Biotechnology (Shanghai) Co., Ltd.

    collaborator INDUSTRY

  • Grit Biotechnology

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-09-26
Primary Completion
2027-11-30
Completion
2028-08-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07205315 on ClinicalTrials.gov